ASCO26: RLTs bring the buzz, but commercial and tolerability qualms remain
Upon its rise to notoriety spearheaded by drugs like Novartis’ Pluvicto (lutetium Lu 177 vipivotide tetraxetan), the radiopharmaceutical field is…
18 Jun 2026
How biotech executives are confronting funding and regulatory shifts
Following an influx of capital in the early COVID-19 pandemic, the biotech sector entered a sustained investment slump. Now the industry finally appears to be signalling renewed momentum. There has…
17 Jun 2026
Can AI predict the (regulatory) future?
The use of AI in pharma has expanded from pilots to function-specific projects with the development of more agile tools. In addition to drug discovery and target identification, many are…
10 Jun 2026
Coya Therapeutics CEO on ALS urgency and fast-tracking COYA 302 for patient impact
As CEO of Coya Therapeutics, Dr Arun Swaminathan is steering the company’s lead programme, COYA 302, an immune-modulating combination designed to restore regulatory T-cell function and dampen neuroinflammation, through a…
10 Jun 2026
Dangerous waters: Geopolitics, supply chains and access to medicines
Shortages of medicines for conditions such as diabetes, attention deficit hyperactivity disorder (ADHD) and hormone replacement therapy (HRT) have long been a feature of the healthcare landscape, but recent events…
09 Jun 2026
Novo Nordisk puts AI at the centre of its clinical strategy
In the last few years, pharma leaders have been scrambling to see how artificial intelligence (AI) can augment every aspect of their business to increase output, accelerate timelines, and slash…
09 Jun 2026
Shift in biosimilar commercial landscape essential for sector sustainability, expert says
As the pharmacological treatment landscape continues to evolve, biologics are becoming increasingly incorporated into therapeutic regimens across a broad range of disease areas. When these branded drugs lose their patent…